UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2023
Commission File Number: 001-37891
AC IMMUNE SA
(Exact name of registrant as specified in its charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Annual General Meeting Results
On June 23, 2023, AC Immune SA (“AC Immune”) held its Annual General Meeting of Shareholders. The Management presentation to shareholders is attached hereto as Exhibit 99.1 and the press release relating to the results of the Annual General Meeting is attached hereto as Exhibit 99.2. The amended Articles of Association are attached hereto as Exhibit 99.3, the notarized version of which will be published on AC Immune’s website (https://ir.acimmune.com/governance) after the filing of the document with the Swiss Register of Commerce. The final results of the remaining agenda items submitted to a vote of the shareholders are as below and the detailed results will be provided in the minutes which will be published on AC Immune’s website (https://ir.acimmune.com/governance) within 15 days:
Agenda Item 1: 2022 IFRS Consolidated Financial Statements, 2022 Statutory Financial Statements and 2022 Compensation Report
Agenda Item 1.1: Approval of 2022 IFRS Consolidated Financial Statements and 2022 Statutory Financial Statements
AC Immune shareholders approved the 2022 IFRS Consolidated Financial Statements and the 2022 Statutory Financial Statements, and took note of the Reports of the Auditors.
Agenda Item 1.2: Advisory Vote on the 2022 Compensation Report
AC Immune shareholders endorsed the 2022 Compensation Report.
Agenda Item 2: Appropriation of Loss
AC Immune shareholders approved that the net loss for the year 2022 in the amount of KCHF 66,936 increases the “accumulated losses brought forward” of KCHF 195,179, resulting in a new balance of “accumulated losses brought forward” of KCHF 262,115.
Agenda Item 3: Discharge of the Board of Directors and of the Executive Committee
AC Immune shareholders approved the discharge of the members of the Board of Directors and of the Executive Committee of their liabilities for their activities in the 2022 financial year.
Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee
Agenda Item 4.1: Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors from 1 July 2023 to 30 June 2024
AC Immune shareholders approved the total maximum amount of compensation for the Board of Directors of CHF 862K (cash-based and equity or equity linked instruments at grant value, excluding employer social security contributions) covering the period from 1 July 2023 to 30 June 2024.
Agenda Item 4.2: Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee for the calendar year 2024
AC Immune shareholders approved the total maximum compensation for the Executive Committee with maximum value of CHF 7,581K (cash-based compensation, variable compensation including equity and equity linked instruments at grant value, excluding employer social security and pension contributions) from 1 January 2024 to 31 December 2024.
Agenda Item 5: Election and re-elections
Agenda Item 5.1: Re-election of Members of the Board of Directors
AC Immune shareholders approved the re-election of Douglas Williams as member and as Chair of the Board of Directors and the re-election of Monika Bütler, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Shaw and Roy Twyman as members of the Board of Directors, each until the end of the Annual General Meeting 2024.
Agenda Item 5.2: Election and re-elections of Members of the Compensation, Nomination and Corporate Governance Committee
AC Immune shareholders approved the election of Monika Bütler and the re-election of Roy Twyman and Douglas Williams as members of the Compensation, Nomination and Corporate Governance Committee, each until the end of the Annual General Meeting 2024.
Agenda Item 5.3: Re-election of the Statutory Auditors
AC Immune shareholders approved the re-election of PricewaterhouseCoopers SA, in Pully, Switzerland, as AC Immune’s statutory auditors for a term of office of one year.
Agenda Item 5.4: Re-election of the Independent Proxy
AC Immune shareholders approved the re-election of Reymond & Associés, Lausanne, as AC Immune’s independent proxy until the end of the Annual General Meeting 2024.
Agenda Item 6: Changes in the Articles of Association
AC Immune shareholders approved certain changes to Article 3b of AC Immune’s Articles of Association relating to conditional capital for bonds and similar debt instruments, enabling the Company to use conditional capital for the issuance of standalone warrants and similar instruments.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | AC IMMUNE SA |
| | | |
| | | |
| | | | By: | /s/ Andrea Pfeifer |
| | | | | Name: | Andrea Pfeifer |
| | | | | Title: | Chief Executive Officer |
| | | | By: | /s/ Christopher Roberts |
| | | | | Name: | Christopher Roberts |
| | | | | Title: | Vice President, Finance and Interim Chief Financial Officer |
Date: June 26, 2023
EXHIBIT INDEX
| Exhibit Number | Description |
| 99.1 | Annual General Meeting presentation |
| 99.2 | Press Release dated June 23, 2023 |
| 99.3 | Articles of Association as of June 23, 2023 |
